-+ 0.00%
-+ 0.00%
-+ 0.00%

According to the Zhitong Finance App, Goli Pharmaceutical-B (01672.HK) announced that it has selected ASC48, a GIPR agonist that is expected to be the first of its kind (first-in-class) oral small molecule, and a fixed-dose compound formulation of the oral GLP-1R agonist ASC30 for clinical development. The ASC30 and ASC48 fixed-dose combination formulation (ASC30_48 FDC) targets GLP-1R and GIPR at the same time, and is expected to be the first “one-pill, once-daily)” oral obesity treatment of its kind.

Zhitongcaijing·07/15/2026 09:57:06
Listen to the news
According to the Zhitong Finance App, Goli Pharmaceutical-B (01672.HK) announced that it has selected ASC48, a GIPR agonist that is expected to be the first of its kind (first-in-class) oral small molecule, and a fixed-dose compound formulation of the oral GLP-1R agonist ASC30 for clinical development. The ASC30 and ASC48 fixed-dose combination formulation (ASC30_48 FDC) targets GLP-1R and GIPR at the same time, and is expected to be the first “one-pill, once-daily)” oral obesity treatment of its kind.